Loading…
Reported covered position: Fellow, Senate Committee on Health, Education, Labor, and Pensions
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Credit for Caring Act of 2025
Client: ASSOCIATION FOR FRONTOTEMPORAL DEGENERATION · Firm: IPOLICY SOLUTIONS
HR 2036 HEALTHY BRAINS Act NOT-OD-26-047: Inviting Comments and Suggestions on a Framework for the NIH-Wide Strategic Plan for Fiscal Years 2027-2031
Credit for Caring Act of 2025
Client: ASSOCIATION FOR FRONTOTEMPORAL DEGENERATION · Firm: IPOLICY SOLUTIONS
HR 8792/S.4513: Multigenerational Caregivers Data Act HR 6766/S3492: Essential Caregivers Act HR 2036/S 925 Credit for Caring Act Docket No. FDA-2026-P-3666-0001: Requests that the FDA codify, regularize, and transparently administer a principle the Agency already recognizes in practice: that the adequacy of an investigation in rare diseases cannot be determined by default assumptions alone. It does not ask FDA to invent a new principle or apply distinct evidentiary thresholds or concessions to rare disease research programs. Drug Repurposing for Unmet Medical Needs; Request for Information (FDA-2026-N-4492) Impacts of Patient-Focused Drug Development Meetings; Establishment of a Public Docket; Request for Information and Comment (FDA-2026-N-3947)
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
TWIST BIOSCIENCE CORPORATION via IPOLICY SOLUTIONS
2026 · third_quarter · Q3
S.3741 - Biosecurity Modernization and Innovation Act of 2026 Regulation for Federal Financial Assistance
H.R.6624/S.3452 - Biological Intellectual Property Protection Act of 2025
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, State, Dept of (DOS)
Source: Senate LDA
| 23ANDME, INC. | 11 | 2019–2022 |
| ASSOCIATION FOR FRONTOTEMPORAL DEGENERATION | 8 | 2025–2026 |
| CLEAR LABS | 6 | 2021–2022 |
| GLOBAL HEALTHY LIVING FOUNDATION | 6 | 2019–2020 |
| GENEDX, INC. | 5 | 2021–2022 |
| INFLECTION MEDICINE | 4 | 2026 |
| CELLINO BIOTECH INC. | 3 | 2023 |
| CHECKERSPOT | 3 | 2026 |
| EVERYLIFE FOUNDATION FOR RARE DISEASES | 3 | 2024 |
| GENOME MEDICAL INC. | 3 | 2019–2020 |
| ONCOCYTE | 3 | 2020–2021 |
| EVANOSTICS | 2 | 2019 |
| GENOMIND INC | 2 | 2019 |
| PIKE THERAPEUTICS | 2 | 2024 |
Patent Eligibility Restoration Act of 2025
Client: ASSOCIATION FOR MOLECULAR PATHOLOGY · Firm: IPOLICY SOLUTIONS
H.R.3152/S.1546: Patent Eligibility Restoration Act
Patent Eligibility Restoration Act of 2025
Client: ASSOCIATION FOR MOLECULAR PATHOLOGY · Firm: IPOLICY SOLUTIONS
H.R.3152/S.1546: Patent Eligibility Restoration Act
P.L. 113-93, Protecting Access to Medicare Act H.R.5269/S.2761 - RESULTS Act CRUSH Request for Information Request for Information: Accelerating the Adoption and Use of Artificial Intelligence as Part of Clinical Care
H.R.5269/S.2761 - RESULTS Act
H.R.5269/S.2761 - RESULTS Act Calendar Year 2027 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Proposed Rule (CMS-1850-P) CY 2027 Payment Policies under the Medicare Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies (CMS-1848-P)
Biological Intellectual Property Protection Act of 2025
Client: TWIST BIOSCIENCE CORPORATION · Firm: IPOLICY SOLUTIONS
H.R.6624/S.3452 - Biological Intellectual Property Protection Act of 2025
Biological Intellectual Property Protection Act of 2025
Client: TWIST BIOSCIENCE CORPORATION · Firm: IPOLICY SOLUTIONS
H.R.6624/S.3452 - Biological Intellectual Property Protection Act of 2025
Biological Intellectual Property Protection Act of 2025
Client: TWIST BIOSCIENCE CORPORATION · Firm: IPOLICY SOLUTIONS
H.R.6624/S.3452 - Biological Intellectual Property Protection Act of 2025
Essential Caregivers Act of 2025
Client: ASSOCIATION FOR FRONTOTEMPORAL DEGENERATION · Firm: IPOLICY SOLUTIONS
HR 8792/S.4513: Multigenerational Caregivers Data Act HR 6766/S3492: Essential Caregivers Act HR 2036/S 925 Credit for Caring Act Docket No. FDA-2026-P-3666-0001: Requests that the FDA codify, regularize, and transparently administer a principle the Agency already recognizes in practice: that the adequacy of an investigation in rare diseases cannot be determined by default assumptions alone. It does not ask FDA to invent a new principle or apply distinct evidentiary thresholds or concessions to rare disease research programs. Drug Repurposing for Unmet Medical Needs; Request for Information (FDA-2026-N-4492) Impacts of Patient-Focused Drug Development Meetings; Establishment of a Public Docket; Request for Information and Comment (FDA-2026-N-3947)
Multigenerational Caregiving Data Act
Client: ASSOCIATION FOR FRONTOTEMPORAL DEGENERATION · Firm: IPOLICY SOLUTIONS
HR 8792/S.4513: Multigenerational Caregivers Data Act HR 6766/S3492: Essential Caregivers Act HR 2036/S 925 Credit for Caring Act Docket No. FDA-2026-P-3666-0001: Requests that the FDA codify, regularize, and transparently administer a principle the Agency already recognizes in practice: that the adequacy of an investigation in rare diseases cannot be determined by default assumptions alone. It does not ask FDA to invent a new principle or apply distinct evidentiary thresholds or concessions to rare disease research programs. Drug Repurposing for Unmet Medical Needs; Request for Information (FDA-2026-N-4492) Impacts of Patient-Focused Drug Development Meetings; Establishment of a Public Docket; Request for Information and Comment (FDA-2026-N-3947)
Enhancing CLIA Act of 2026
Client: ASSOCIATION FOR MOLECULAR PATHOLOGY · Firm: IPOLICY SOLUTIONS
H.R. 8890: Enhancing CLIA Act of 2026
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Client: ASSOCIATION FOR FRONTOTEMPORAL DEGENERATION · Firm: IPOLICY SOLUTIONS
H.R.9260: Labor, Health and Human Services, Education, and Related Agencies FY 2027 No bill number, Senate: Defense FY 2027
Patent Eligibility Restoration Act of 2025
Client: ASSOCIATION FOR MOLECULAR PATHOLOGY · Firm: IPOLICY SOLUTIONS
H.R.3152/S.1546: Patent Eligibility Restoration Act
Patent Eligibility Restoration Act of 2025
Client: ASSOCIATION FOR MOLECULAR PATHOLOGY · Firm: IPOLICY SOLUTIONS
H.R.3152/S.1546: Patent Eligibility Restoration Act
P.L. 113-93, Protecting Access to Medicare Act H.R.5269/S.2761 - RESULTS Act CRUSH Request for Information Request for Information: Accelerating the Adoption and Use of Artificial Intelligence as Part of Clinical Care
H.R.5269/S.2761 - RESULTS Act Calendar Year 2027 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Proposed Rule (CMS-1850-P) CY 2027 Payment Policies under the Medicare Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies (CMS-1848-P)
H.R.5269/S.2761 - RESULTS Act
Biological Intellectual Property Protection Act of 2025
Client: TWIST BIOSCIENCE CORPORATION · Firm: IPOLICY SOLUTIONS
H.R.6624/S.3452 - Biological Intellectual Property Protection Act of 2025
Biological Intellectual Property Protection Act of 2025
Client: TWIST BIOSCIENCE CORPORATION · Firm: IPOLICY SOLUTIONS
H.R.6624/S.3452 - Biological Intellectual Property Protection Act of 2025
Biological Intellectual Property Protection Act of 2025
Client: TWIST BIOSCIENCE CORPORATION · Firm: IPOLICY SOLUTIONS
H.R.6624/S.3452 - Biological Intellectual Property Protection Act of 2025
Essential Caregivers Act of 2025
Client: ASSOCIATION FOR FRONTOTEMPORAL DEGENERATION · Firm: IPOLICY SOLUTIONS
HR 8792/S.4513: Multigenerational Caregivers Data Act HR 6766/S3492: Essential Caregivers Act HR 2036/S 925 Credit for Caring Act Docket No. FDA-2026-P-3666-0001: Requests that the FDA codify, regularize, and transparently administer a principle the Agency already recognizes in practice: that the adequacy of an investigation in rare diseases cannot be determined by default assumptions alone. It does not ask FDA to invent a new principle or apply distinct evidentiary thresholds or concessions to rare disease research programs. Drug Repurposing for Unmet Medical Needs; Request for Information (FDA-2026-N-4492) Impacts of Patient-Focused Drug Development Meetings; Establishment of a Public Docket; Request for Information and Comment (FDA-2026-N-3947)
Biosecurity Modernization and Innovation Act of 2026
Client: TWIST BIOSCIENCE CORPORATION · Firm: IPOLICY SOLUTIONS
S.3741 - Biosecurity Modernization and Innovation Act of 2026
Biosecurity Modernization and Innovation Act of 2026
Client: TWIST BIOSCIENCE CORPORATION · Firm: IPOLICY SOLUTIONS
S.3741 - Biosecurity Modernization and Innovation Act of 2026 Regulation for Federal Financial Assistance
Biosecurity Modernization and Innovation Act of 2026
Client: TWIST BIOSCIENCE CORPORATION · Firm: IPOLICY SOLUTIONS
S.3741 - Biosecurity Modernization and Innovation Act of 2026
Multigenerational Caregiving Data Act
Client: ASSOCIATION FOR FRONTOTEMPORAL DEGENERATION · Firm: IPOLICY SOLUTIONS
HR 8792/S.4513: Multigenerational Caregivers Data Act HR 6766/S3492: Essential Caregivers Act HR 2036/S 925 Credit for Caring Act Docket No. FDA-2026-P-3666-0001: Requests that the FDA codify, regularize, and transparently administer a principle the Agency already recognizes in practice: that the adequacy of an investigation in rare diseases cannot be determined by default assumptions alone. It does not ask FDA to invent a new principle or apply distinct evidentiary thresholds or concessions to rare disease research programs. Drug Repurposing for Unmet Medical Needs; Request for Information (FDA-2026-N-4492) Impacts of Patient-Focused Drug Development Meetings; Establishment of a Public Docket; Request for Information and Comment (FDA-2026-N-3947)
Credit for Caring Act of 2025
Client: ASSOCIATION FOR FRONTOTEMPORAL DEGENERATION · Firm: IPOLICY SOLUTIONS
HR 8792/S.4513: Multigenerational Caregivers Data Act HR 6766/S3492: Essential Caregivers Act HR 2036/S 925 Credit for Caring Act Docket No. FDA-2026-P-3666-0001: Requests that the FDA codify, regularize, and transparently administer a principle the Agency already recognizes in practice: that the adequacy of an investigation in rare diseases cannot be determined by default assumptions alone. It does not ask FDA to invent a new principle or apply distinct evidentiary thresholds or concessions to rare disease research programs. Drug Repurposing for Unmet Medical Needs; Request for Information (FDA-2026-N-4492) Impacts of Patient-Focused Drug Development Meetings; Establishment of a Public Docket; Request for Information and Comment (FDA-2026-N-3947)
To prohibit the use of Federal funds to implement, administer, or enforce a final rule of the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests", and for other purposes.
Client: ASSOCIATION FOR MOLECULAR PATHOLOGY · Firm: IPOLICY SOLUTIONS
No bill #: legislation to clarify CLIA FDA Final Rule: Laboratory Developed Tests S.J.Res.82 - A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests" HR 1463: Freedom for Laboratory Innovation and Testing Act
To prohibit the use of Federal funds to implement, administer, or enforce a final rule of the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests", and for other purposes.
Client: ASSOCIATION FOR MOLECULAR PATHOLOGY · Firm: IPOLICY SOLUTIONS
No bill #: legislation to clarify CLIA FDA Final Rule: Laboratory Developed Tests S.J.Res.82 - A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests" HR 1463: Freedom for Laboratory Innovation and Testing Act
Full-Year Continuing Appropriations and Extensions Act, 2025
Client: ASSOCIATION FOR FRONTOTEMPORAL DEGENERATION · Firm: IPOLICY SOLUTIONS
No bill number: Labor, Health and Human Services, Education, and Related Agencies FY 2026 No bill number: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies FY 2026 H.R. 1968: FY2025 Full-Year Continuing Appropriations and Extensions Act
Credit for Caring Act of 2025
Client: ASSOCIATION FOR FRONTOTEMPORAL DEGENERATION · Firm: IPOLICY SOLUTIONS
H.R. 2036/ S.925: Credit for Caring Act
Credit for Caring Act of 2025
Client: ASSOCIATION FOR FRONTOTEMPORAL DEGENERATION · Firm: IPOLICY SOLUTIONS
H.R. 2036/ S.925: Credit for Caring Act
Credit for Caring Act of 2025
Client: ASSOCIATION FOR FRONTOTEMPORAL DEGENERATION · Firm: IPOLICY SOLUTIONS
H.R. 2036/ S.925: Credit for Caring Act
Right Drug Dose Now Act of 2025
Client: ASSOCIATION FOR MOLECULAR PATHOLOGY · Firm: IPOLICY SOLUTIONS
HR 2471: Right Drug Dose Now Act
To amend the Research and Development, Competition, and Innovation Act to support nucleic acid screening, and for other purposes.
Client: TWIST BIOSCIENCE CORPORATION · Firm: IPOLICY SOLUTIONS
No bill #: Securing Gene Synthesis Act No bill #: Gene Synthesis Safety and Security Act H.R. 3029: Nucleic Acid Standards for Biosecurity Act
Patent Eligibility Restoration Act of 2025
Client: ASSOCIATION FOR MOLECULAR PATHOLOGY · Firm: IPOLICY SOLUTIONS
H.R.3152/S.1546: Patent Eligibility Restoration Act
Patent Eligibility Restoration Act of 2025
Client: ASSOCIATION FOR MOLECULAR PATHOLOGY · Firm: IPOLICY SOLUTIONS
H.R.3152/S.1546: Patent Eligibility Restoration Act
Patent Eligibility Restoration Act of 2025
Client: ASSOCIATION FOR MOLECULAR PATHOLOGY · Firm: IPOLICY SOLUTIONS
H.R.3152/S.1546: Patent Eligibility Restoration Act
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: ASSOCIATION FOR MOLECULAR PATHOLOGY · Firm: IPOLICY SOLUTIONS
H.R.4121: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
P.L. 113-93, Protecting Access to Medicare Act H.R.5269/S.2761 - RESULTS Act
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: ASSOCIATION FOR FRONTOTEMPORAL DEGENERATION · Firm: IPOLICY SOLUTIONS
H.R. 5304/S. 2587: Labor, Health and Human Services, Education, and Related Agencies FY 2026
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: ASSOCIATION FOR FRONTOTEMPORAL DEGENERATION · Firm: IPOLICY SOLUTIONS
H.R. 5304/S. 2587: Labor, Health and Human Services, Education, and Related Agencies FY 2026
Biological Intellectual Property Protection Act of 2025
Client: TWIST BIOSCIENCE CORPORATION · Firm: IPOLICY SOLUTIONS
H.R.6624/S.3452 - Biological Intellectual Property Protection Act of 2025 Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Robotics and Industrial Machinery (Docket No. 250924-0161 / XRIN 0694-XC138)
HR 694/S 206 Restoring Trade Fairness Act
National Defense Authorization Act for Fiscal Year 2026
Client: TWIST BIOSCIENCE CORPORATION · Firm: IPOLICY SOLUTIONS
S.1071 - National Defense Authorization Act for Fiscal Year 2026
Patent Eligibility Restoration Act of 2025
Client: ASSOCIATION FOR MOLECULAR PATHOLOGY · Firm: IPOLICY SOLUTIONS
H.R.3152/S.1546: Patent Eligibility Restoration Act
Patent Eligibility Restoration Act of 2025
Client: ASSOCIATION FOR MOLECULAR PATHOLOGY · Firm: IPOLICY SOLUTIONS
H.R.3152/S.1546: Patent Eligibility Restoration Act
Patent Eligibility Restoration Act of 2025
Client: ASSOCIATION FOR MOLECULAR PATHOLOGY · Firm: IPOLICY SOLUTIONS
H.R.3152/S.1546: Patent Eligibility Restoration Act
Patent Eligibility Restoration Act of 2025
Client: TWIST BIOSCIENCE CORPORATION · Firm: IPOLICY SOLUTIONS
Intellectual property theft S.1546: Patent Eligibility Restoration Act
HR 694/S 206 Restoring Trade Fairness Act
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: ASSOCIATION FOR FRONTOTEMPORAL DEGENERATION · Firm: IPOLICY SOLUTIONS
H.R. 5304/S. 2587: Labor, Health and Human Services, Education, and Related Agencies FY 2026
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: ASSOCIATION FOR FRONTOTEMPORAL DEGENERATION · Firm: IPOLICY SOLUTIONS
H.R. 5304/S. 2587: Labor, Health and Human Services, Education, and Related Agencies FY 2026
P.L. 113-93, Protecting Access to Medicare Act H.R.5269/S.2761 - RESULTS Act
Biological Intellectual Property Protection Act of 2025
Client: TWIST BIOSCIENCE CORPORATION · Firm: IPOLICY SOLUTIONS
H.R.6624/S.3452 - Biological Intellectual Property Protection Act of 2025 Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Robotics and Industrial Machinery (Docket No. 250924-0161 / XRIN 0694-XC138)
Credit for Caring Act of 2025
Client: ASSOCIATION FOR FRONTOTEMPORAL DEGENERATION · Firm: IPOLICY SOLUTIONS
H.R. 2036/ S.925: Credit for Caring Act
Credit for Caring Act of 2025
Client: ASSOCIATION FOR FRONTOTEMPORAL DEGENERATION · Firm: IPOLICY SOLUTIONS
H.R. 2036/ S.925: Credit for Caring Act
Credit for Caring Act of 2025
Client: ASSOCIATION FOR FRONTOTEMPORAL DEGENERATION · Firm: IPOLICY SOLUTIONS
H.R. 2036/ S.925: Credit for Caring Act
A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests".
Client: ASSOCIATION FOR MOLECULAR PATHOLOGY · Firm: IPOLICY SOLUTIONS
No bill #: legislation to clarify CLIA FDA Final Rule: Laboratory Developed Tests S.J.Res.82 - A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests" HR 1463: Freedom for Laboratory Innovation and Testing Act
A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests".
Client: ASSOCIATION FOR MOLECULAR PATHOLOGY · Firm: IPOLICY SOLUTIONS
No bill #: legislation to clarify CLIA FDA Final Rule: Laboratory Developed Tests S.J.Res.82 - A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests" HR 1463: Freedom for Laboratory Innovation and Testing Act
No bill #: legislation to modernize CLIA H.R.2369 - VALID Act of 2023 FDA Final Rule: Laboratory Developed Tests S.J.Res.82 - A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests"
No bill #: legislation to clarify CLIA H.R.2369 - VALID Act of 2023 FDA Final Rule: Laboratory Developed Tests S.J.Res.82 - A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests"
No bill #: legislation to modernize CLIA H.R.2369 - VALID Act of 2023 FDA Proposed Rulemaking on LDTs
H.R.2369 - VALID Act of 2023 FDA Final Rule: Laboratory Developed Tests
H.R.2369 - VALID Act of 2023 FDA Proposed rule on LDTs
No bill #: legislation to modernize CLIA H.R.2369 - VALID Act of 2023 FDA Final Rule: Laboratory Developed Tests S.J.Res.82 - A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests"
Preparing for All Hazards and Pathogens Reauthorization Act
Client: TWIST BIOSCIENCE CORPORATION · Firm: IPOLICY SOLUTIONS
S. 2333: Pandemic All Hazards Preparedness Authorization Act H.R.4702/S.2400 - Securing Gene Synthesis Act H.R. 4421: Preparing for All Hazards and Pathogens Reauthorization Act
H.R.4702/S.2400 - Securing Gene Synthesis Act S.2356 - Gene Synthesis Safety and Security Act
H.R.4702/S.2400 - Securing Gene Synthesis Act S.2356 - Gene Synthesis Safety and Security Act H.R. 9194 - Nucleic Acids Standards for Biosecurity Act
H.R.4702/S.2400 - Securing Gene Synthesis Act S.2356 - Gene Synthesis Safety and Security Act H.R. 9194 - Nucleic Acids Standards for Biosecurity Act
S. 2333: Pandemic All Hazards Preparedness Authorization Act H.R.4702/S.2400 - Securing Gene Synthesis Act H.R. 4421: Preparing for All Hazards and Pathogens Reauthorization Act
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2025
Client: TWIST BIOSCIENCE CORPORATION · Firm: IPOLICY SOLUTIONS
HR 9026: FY2025 Commerce, Justice, Science and Related Agencies
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2025
Client: TWIST BIOSCIENCE CORPORATION · Firm: IPOLICY SOLUTIONS
HR 9026: FY2025 Commerce, Justice, Science and Related Agencies
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2025
Client: ASSOCIATION FOR MOLECULAR PATHOLOGY · Firm: IPOLICY SOLUTIONS
H.R. 9027/S. 4690 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2025
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2025
Client: ASSOCIATION FOR MOLECULAR PATHOLOGY · Firm: IPOLICY SOLUTIONS
H.R. 9027/S. 4690 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2025
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2025
Client: ASSOCIATION FOR MOLECULAR PATHOLOGY · Firm: IPOLICY SOLUTIONS
H.R. 9027/S. 4690 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2025
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2025
Client: EVERYLIFE FOUNDATION FOR RARE DISEASES · Firm: IPOLICY SOLUTIONS
H.R. 9027/S. 4690 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2025
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2025
Client: EVERYLIFE FOUNDATION FOR RARE DISEASES · Firm: IPOLICY SOLUTIONS
H.R. 9027/S. 4690 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2025
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Client: INVITAE INC. · Firm: IPOLICY SOLUTIONS
H.R. 9029 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Nucleic Acid Standards for Biosecurity Act
Client: TWIST BIOSCIENCE CORPORATION · Firm: IPOLICY SOLUTIONS
H.R.4702/S.2400 - Securing Gene Synthesis Act S.2356 - Gene Synthesis Safety and Security Act H.R. 9194 - Nucleic Acids Standards for Biosecurity Act
Nucleic Acid Standards for Biosecurity Act
Client: TWIST BIOSCIENCE CORPORATION · Firm: IPOLICY SOLUTIONS
H.R.4702/S.2400 - Securing Gene Synthesis Act S.2356 - Gene Synthesis Safety and Security Act H.R. 9194 - Nucleic Acids Standards for Biosecurity Act
Patent Eligibility Restoration Act of 2023
Client: ASSOCIATION FOR MOLECULAR PATHOLOGY · Firm: IPOLICY SOLUTIONS
S.2140: Patent Eligibility Restoration Act of 2023
Patent Eligibility Restoration Act of 2023
Client: TWIST BIOSCIENCE CORPORATION · Firm: IPOLICY SOLUTIONS
S2140 Patent Eligibility Restoration Act Intellectual property theft
Patent Eligibility Restoration Act of 2023
Client: ASSOCIATION FOR MOLECULAR PATHOLOGY · Firm: IPOLICY SOLUTIONS
S.2140: Patent Eligibility Restoration Act of 2023
Patent Eligibility Restoration Act of 2023
Client: ASSOCIATION FOR MOLECULAR PATHOLOGY · Firm: IPOLICY SOLUTIONS
S.2140: Patent Eligibility Restoration Act of 2023
S.2140: Patent Eligibility Restoration Act
Patent Eligibility Restoration Act of 2023
Client: ASSOCIATION FOR MOLECULAR PATHOLOGY · Firm: IPOLICY SOLUTIONS
S.2140: Patent Eligibility Restoration Act of 2023
Pandemic and All-Hazards Preparedness and Response Act
Client: TWIST BIOSCIENCE CORPORATION · Firm: IPOLICY SOLUTIONS
S. 2333: Pandemic All Hazards Preparedness Authorization Act H.R.4702/S.2400 - Securing Gene Synthesis Act H.R. 4421: Preparing for All Hazards and Pathogens Reauthorization Act
Gene Synthesis Safety and Security Act
Client: TWIST BIOSCIENCE CORPORATION · Firm: IPOLICY SOLUTIONS
H.R.4702/S.2400 - Securing Gene Synthesis Act S.2356 - Gene Synthesis Safety and Security Act H.R. 9194 - Nucleic Acids Standards for Biosecurity Act
Gene Synthesis Safety and Security Act
Client: TWIST BIOSCIENCE CORPORATION · Firm: IPOLICY SOLUTIONS
H.R.4702/S.2400 - Securing Gene Synthesis Act S.2356 - Gene Synthesis Safety and Security Act H.R. 9194 - Nucleic Acids Standards for Biosecurity Act
Gene Synthesis Safety and Security Act
Client: TWIST BIOSCIENCE CORPORATION · Firm: IPOLICY SOLUTIONS
H.R.4702/S.2400 - Securing Gene Synthesis Act S.2356 - Gene Synthesis Safety and Security Act
H.R.4702/S.2400 - Securing Gene Synthesis Act S.2356 - Gene Synthesis Safety and Security Act H.R. 9194 - Nucleic Acids Standards for Biosecurity Act
S. 2333: Pandemic All Hazards Preparedness Authorization Act H.R.4702/S.2400 - Securing Gene Synthesis Act H.R. 4421: Preparing for All Hazards and Pathogens Reauthorization Act
H.R.4702/S.2400 - Securing Gene Synthesis Act S.2356 - Gene Synthesis Safety and Security Act
H.R.4702/S.2400 - Securing Gene Synthesis Act S.2356 - Gene Synthesis Safety and Security Act H.R. 9194 - Nucleic Acids Standards for Biosecurity Act
Cannabis Administration and Opportunity Act
Client: PIKE THERAPEUTICS · Firm: IPOLICY SOLUTIONS
S4226 Cannabis Administration and Opportunity Act Parkinson's disease treatment
Improving Seniors’ Timely Access to Care Act of 2024
Client: GUARDANT HEALTH INC. · Firm: IPOLICY SOLUTIONS
S4532 Seniors' Timely Access to Care Act Request for Information on Medicare Advantage (CMS-4207-NC)
Improving Seniors’ Timely Access to Care Act of 2024
Client: GUARDANT HEALTH INC. · Firm: IPOLICY SOLUTIONS
S4532 Seniors' Timely Access to Care Act Calendar Year 2025 Payment Policies under the Physician Fee Schedule (PFS) and Other Changes to Part B Payment and Coverage Policies CY 2025 Medicare Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System Proposed Rule
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2025
Client: ASSOCIATION FOR MOLECULAR PATHOLOGY · Firm: IPOLICY SOLUTIONS
H.R. 9027/S. 4690 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2025
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2025
Client: EVERYLIFE FOUNDATION FOR RARE DISEASES · Firm: IPOLICY SOLUTIONS
H.R. 9027/S. 4690 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2025
2026 · third_quarter · Q3
Food products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INFLECTION MEDICINE via IPOLICY SOLUTIONS
2026 · third_quarter · Q3
Request for Information; Clinical Laboratory Improvement Amendments of 1988 (CLIA) Regulations (CMS-3485-NC)
CY 2027 Payment Policies under the Medicare Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies (CMS-1848-P)
No Bill Number: Labor, Health and Human Services, Education, and Related Agencies FY 2027 No Bill Number: Financial Services and General Government Appropriations Act, 2027
Electronic health record interoperability and information blocking
Filing targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE
ASSOCIATION FOR FRONTOTEMPORAL DEGENERATION via IPOLICY SOLUTIONS
2026 · third_quarter · Q3
Regulation for Federal Financial Assistance
Request for Information; Comprehensive Review of the Essential Health Benefits Framework and Typical Employer Plan Standard HHS Request for Comment on the Update to the National Plan To Address Alzheimer's Disease RFI on Commonsense Policy Options to Lower Drug Prices for Patients Medicare and State Health Care Programs: Fraud and Abuse; Request for Information Regarding the Federal Anti-Kickback Statute and Beneficiary Inducements CMP FDA clinical trial design requirements RFI on Health Coverage That Works for Everyone Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
GUARDANT HEALTH INC. via IPOLICY SOLUTIONS
2026 · third_quarter · Q3
Request for Information; Clinical Laboratory Improvement Amendments of 1988 (CLIA) Regulations (CMS-3485-NC)
CY 2027 Payment Policies under the Medicare Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies (CMS-1848-P) Medicare Program; Regulatory Alignment for Predictable and Immediate Device (RAPID) Coverage Pathway (CMS-3487-NC)
Filing targets: Centers For Medicare and Medicaid Services (CMS)
ASSOCIATION FOR MOLECULAR PATHOLOGY via IPOLICY SOLUTIONS
2026 · third_quarter · Q3
Request for Information; Clinical Laboratory Improvement Amendments of 1988 (CLIA) Regulations (CMS-3485-NC) Regulation for Federal Financial Assistance
H.R.5269/S.2761 - RESULTS Act Calendar Year 2027 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Proposed Rule (CMS-1850-P) CY 2027 Payment Policies under the Medicare Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies (CMS-1848-P)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
CHECKERSPOT via IPOLICY SOLUTIONS
2026 · second_quarter · Q2
Food products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHECKERSPOT via IPOLICY SOLUTIONS
2026 · second_quarter · RR
Food products
INFLECTION MEDICINE via IPOLICY SOLUTIONS
2026 · second_quarter · Q2
No Bill Number: Labor, Health and Human Services, Education, and Related Agencies FY 2027 No Bill Number: Financial Services and General Government Appropriations Act, 2027
Filing targets: SENATE
ASSOCIATION FOR FRONTOTEMPORAL DEGENERATION via IPOLICY SOLUTIONS
2026 · second_quarter · Q2
HR 8792/S.4513: Multigenerational Caregivers Data Act HR 6766/S3492: Essential Caregivers Act HR 2036/S 925 Credit for Caring Act Docket No. FDA-2026-P-3666-0001: Requests that the FDA codify, regularize, and transparently administer a principle the Agency already recognizes in practice: that the adequacy of an investigation in rare diseases cannot be determined by default assumptions alone. It does not ask FDA to invent a new principle or apply distinct evidentiary thresholds or concessions to rare disease research programs. Drug Repurposing for Unmet Medical Needs; Request for Information (FDA-2026-N-4492) Impacts of Patient-Focused Drug Development Meetings; Establishment of a Public Docket; Request for Information and Comment (FDA-2026-N-3947)
HR 2036 HEALTHY BRAINS Act NOT-OD-26-047: Inviting Comments and Suggestions on a Framework for the NIH-Wide Strategic Plan for Fiscal Years 2027-2031
GUARDANT HEALTH INC. via IPOLICY SOLUTIONS
2026 · second_quarter · Q2
Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; Interoperability Standards for Prior Authorization (CMS-0068-P)
Filing targets: Centers For Medicare and Medicaid Services (CMS)
TWIST BIOSCIENCE CORPORATION via IPOLICY SOLUTIONS
2026 · second_quarter · Q2
H.R.6624/S.3452 - Biological Intellectual Property Protection Act of 2025
S.3741 - Biosecurity Modernization and Innovation Act of 2026
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASSOCIATION FOR MOLECULAR PATHOLOGY via IPOLICY SOLUTIONS
2026 · second_quarter · Q2
H.R.3152/S.1546: Patent Eligibility Restoration Act
H.R. 8890: Enhancing CLIA Act of 2026
H.R.5269/S.2761 - RESULTS Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
INFLECTION MEDICINE via IPOLICY SOLUTIONS
2026 · first_quarter · Q1
No Bill Number: Labor, Health and Human Services, Education, and Related Agencies FY 2027 No Bill Number: Financial Services and General Government Appropriations Act, 2027
Filing targets: SENATE
TWIST BIOSCIENCE CORPORATION via IPOLICY SOLUTIONS
2026 · first_quarter · Q1
H.R.6624/S.3452 - Biological Intellectual Property Protection Act of 2025
S.3741 - Biosecurity Modernization and Innovation Act of 2026
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS)
INFLECTION MEDICINE via IPOLICY SOLUTIONS
2026 · first_quarter · RR
FY27 LHHS Appropriations FY27 Financial Services and General Government Appropriations
ASSOCIATION FOR FRONTOTEMPORAL DEGENERATION via IPOLICY SOLUTIONS
2026 · first_quarter · Q1
CMS-9883-P: Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2027; and Basic Health Program
No Bill Number: Labor, Health and Human Services, Education, and Related Agencies FY 2027
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
GUARDANT HEALTH INC. via IPOLICY SOLUTIONS
2026 · first_quarter · Q1
CRUSH RFI CMS-9883-P: Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2027; and Basic Health Program Contract Year 2027 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program (CMS-4212-P)
FDA-2025-N-4622 Immunology and Microbiology Devices; Reclassification of Nucleic Acid-Based Test Systems for Use with a Corresponding Approved Oncology Therapeutic Product; Proposed Amendment; Proposed Order
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA)
ASSOCIATION FOR MOLECULAR PATHOLOGY via IPOLICY SOLUTIONS
2026 · first_quarter · Q1
H.R.3152/S.1546: Patent Eligibility Restoration Act
No bill #: legislation to clarify CLIA
P.L. 113-93, Protecting Access to Medicare Act H.R.5269/S.2761 - RESULTS Act CRUSH Request for Information Request for Information: Accelerating the Adoption and Use of Artificial Intelligence as Part of Clinical Care
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TWIST BIOSCIENCE CORPORATION via IPOLICY SOLUTIONS
2025 · fourth_quarter · Q4
Gene synthesis screening
S.1071 - National Defense Authorization Act for Fiscal Year 2026
H.R.6624/S.3452 - Biological Intellectual Property Protection Act of 2025 Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Robotics and Industrial Machinery (Docket No. 250924-0161 / XRIN 0694-XC138)
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE
ASSOCIATION FOR FRONTOTEMPORAL DEGENERATION via IPOLICY SOLUTIONS
2025 · fourth_quarter · Q4
H.R. 5304/S. 2587: Labor, Health and Human Services, Education, and Related Agencies FY 2026
H.R. 2036/ S.925: Credit for Caring Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GUARDANT HEALTH INC. via IPOLICY SOLUTIONS
2025 · fourth_quarter · Q4
Quality measures in Medicare and colorectal cancer screening Utilization management in Medicare Advantage
Filing targets: Centers For Medicare and Medicaid Services (CMS)
ASSOCIATION FOR MOLECULAR PATHOLOGY via IPOLICY SOLUTIONS
2025 · fourth_quarter · Q4
No bill #: legislation to clarify CLIA
H.R.3152/S.1546: Patent Eligibility Restoration Act
P.L. 113-93, Protecting Access to Medicare Act H.R.5269/S.2761 - RESULTS Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE
ASSOCIATION FOR FRONTOTEMPORAL DEGENERATION via IPOLICY SOLUTIONS
2025 · third_quarter · Q3
H.R. 5304/S. 2587: Labor, Health and Human Services, Education, and Related Agencies FY 2026
Medical research workforce issues Facility and Administrative Costs
Public Law No: 119-21: One Big Beautiful Bill
GUARDANT HEALTH INC. via IPOLICY SOLUTIONS
2025 · third_quarter · Q3
CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program Quality measures in Medicare and colorectal cancer screening
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
TWIST BIOSCIENCE CORPORATION via IPOLICY SOLUTIONS
2025 · third_quarter · Q3
American competitiveness in synthetic biology No bill #: BIOCOMPETE Act
Intellectual property theft S.1546: Patent Eligibility Restoration Act
Gene synthesis screening
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE
ASSOCIATION FOR MOLECULAR PATHOLOGY via IPOLICY SOLUTIONS
2025 · third_quarter · Q3
No bill #: legislation to clarify CLIA FDA Final Rule: Laboratory Developed Tests
H.R.3152/S.1546: Patent Eligibility Restoration Act
P.L. 113-93, Protecting Access to Medicare Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
TWIST BIOSCIENCE CORPORATION via IPOLICY SOLUTIONS
2025 · second_quarter · Q2
American competitiveness in synthetic biology No bill #: BIOCOMPETE Act
Intellectual property theft
Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients - Docket No. BIS-2025-0022 / XRIN 0694-XC120
ASSOCIATION FOR FRONTOTEMPORAL DEGENERATION via IPOLICY SOLUTIONS
2025 · second_quarter · Q2
No bill #: Labor, Health and Human Services, Education, and Related Agencies FY 2026
Medical research workforce issues Facility and Administrative Costs
Public Law No: 119-21: One Big Beautiful Bill
GUARDANT HEALTH INC. via IPOLICY SOLUTIONS
2025 · second_quarter · Q2
CMS RFI on Deregulation: ADLT requirements, Medicare Advantage coverage determination process, NCD process, laboratory test date of service, quality measures
Filing targets: Centers For Medicare and Medicaid Services (CMS)
ASSOCIATION FOR MOLECULAR PATHOLOGY via IPOLICY SOLUTIONS
2025 · second_quarter · Q2
No bill #: legislation to clarify CLIA FDA Final Rule: Laboratory Developed Tests S.J.Res.82 - A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests" HR 1463: Freedom for Laboratory Innovation and Testing Act
H.R.3152/S.1546: Patent Eligibility Restoration Act
H.R.4121: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
TWIST BIOSCIENCE CORPORATION via IPOLICY SOLUTIONS
2025 · first_quarter · Q1
Securing Gene Synthesis Act Gene Synthesis Safety and Security Act
American competitiveness in synthetic biology No bill #: BIOCOMPETE Act
Intellectual property theft
ASSOCIATION FOR FRONTOTEMPORAL DEGENERATION via IPOLICY SOLUTIONS
2025 · first_quarter · Q1
Rare Disease Therapeutic Development
No bill number: Labor, Health and Human Services, Education, and Related Agencies FY 2026 No bill number: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies FY 2026 H.R. 1968: FY2025 Full-Year Continuing Appropriations and Extensions Act
Medical research workforce issues Facility and Administrative Costs
GUARDANT HEALTH INC. via IPOLICY SOLUTIONS
2025 · first_quarter · Q1
Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (CMS-4208-P).
Filing targets: Centers For Medicare and Medicaid Services (CMS)
ASSOCIATION FOR MOLECULAR PATHOLOGY via IPOLICY SOLUTIONS
2025 · first_quarter · Q1
No bill #: legislation to clarify CLIA FDA Final Rule: Laboratory Developed Tests S.J.Res.82 - A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests" HR 1463: Freedom for Laboratory Innovation and Testing Act
No bill #: Patent Eligibility Restoration Act
No bill number: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
ASSOCIATION FOR FRONTOTEMPORAL DEGENERATION via IPOLICY SOLUTIONS
2025 · first_quarter · RR
Biomedical research for frontotemporal degeneration and related dementias Caregiver support
TWIST BIOSCIENCE CORPORATION via IPOLICY SOLUTIONS
2024 · fourth_quarter · Q4
H.R.4702/S.2400 - Securing Gene Synthesis Act S.2356 - Gene Synthesis Safety and Security Act H.R. 9194 - Nucleic Acids Standards for Biosecurity Act
American competitiveness in synthetic biology No bill #: BIOCOMPETE Act
Intellectual property theft
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASSOCIATION FOR MOLECULAR PATHOLOGY via IPOLICY SOLUTIONS
2024 · fourth_quarter · Q4
Preliminary Determinations for Calendar Year (CY) 2025 for New and Reconsidered Services on the Clinical Laboratory Fee Schedule (CLFS) Request for Information concerning consolidation of A/B Medicare Administrative Contractors (MACs) for Jurisdiction 5 (J5) and A/B HH+H MAC Jurisdiction 6 (J6) into Jurisdiction G; for consolidation of A/B MAC Jurisdiction 8 (J8) and A/B HH+H MAC Jurisdiction 15 (J15) into Jurisdiction Q; and 10-Year MAC Contract Award Period of Performance
S.2140: Patent Eligibility Restoration Act of 2023
No bill #: legislation to clarify CLIA H.R.2369 - VALID Act of 2023 FDA Final Rule: Laboratory Developed Tests S.J.Res.82 - A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests"
TWIST BIOSCIENCE CORPORATION via IPOLICY SOLUTIONS
2024 · third_quarter · Q3
HR 9026: FY2025 Commerce, Justice, Science and Related Agencies
H.R.4702/S.2400 - Securing Gene Synthesis Act S.2356 - Gene Synthesis Safety and Security Act H.R. 9194 - Nucleic Acids Standards for Biosecurity Act
American competitiveness in synthetic biology No bill #: BIOCOMPETE Act
EVERYLIFE FOUNDATION FOR RARE DISEASES via IPOLICY SOLUTIONS
2024 · third_quarter · Q3
H.R. 9027/S. 4690 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2025
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GUARDANT HEALTH INC. via IPOLICY SOLUTIONS
2024 · third_quarter · Q3
S4532 Seniors' Timely Access to Care Act Calendar Year 2025 Payment Policies under the Physician Fee Schedule (PFS) and Other Changes to Part B Payment and Coverage Policies CY 2025 Medicare Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System Proposed Rule
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
INVITAE INC. via IPOLICY SOLUTIONS
2024 · third_quarter · 3T
No bill #: Precision Medicine Access for Kids Today Act
Filing targets: HOUSE OF REPRESENTATIVES
ASSOCIATION FOR MOLECULAR PATHOLOGY via IPOLICY SOLUTIONS
2024 · third_quarter · Q3
H.R. 9027/S. 4690 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2025
No bill #: legislation to modernize CLIA H.R.2369 - VALID Act of 2023 FDA Final Rule: Laboratory Developed Tests S.J.Res.82 - A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests"
No bill number, Cures 2.0 FDA-2024-D-0083, Enforcement Policy for Certain In Vitro Diagnostic Devices for Immediate Public Health Response in the Absence of a Declaration under Section 564 FDA-2023-D-5365, Consideration of Enforcement Policies for Tests During a Section 564 Declared Emergency
TWIST BIOSCIENCE CORPORATION via IPOLICY SOLUTIONS
2024 · second_quarter · Q2
HR 9026: FY2025 Commerce, Justice, Science and Related Agencies
American competitiveness in synthetic biology No bill #: BIOCOMPETE Act
H.R.4702/S.2400 - Securing Gene Synthesis Act S.2356 - Gene Synthesis Safety and Security Act
PIKE THERAPEUTICS via IPOLICY SOLUTIONS
2024 · second_quarter · Q2
S4226 Cannabis Administration and Opportunity Act Parkinson's disease treatment
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EVERYLIFE FOUNDATION FOR RARE DISEASES via IPOLICY SOLUTIONS
2024 · second_quarter · Q2
H.R. 9027/S. 4690 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2025
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GUARDANT HEALTH INC. via IPOLICY SOLUTIONS
2024 · second_quarter · Q2
S4532 Seniors' Timely Access to Care Act Request for Information on Medicare Advantage (CMS-4207-NC)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
INVITAE INC. via IPOLICY SOLUTIONS
2024 · second_quarter · Q2
H.R.2369 - VALID Act of 2023 FDA Final Rule: Laboratory Developed Tests
No bill #: Precision Medicine Access for Kids Today Act
H.R. 9029 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ASSOCIATION FOR MOLECULAR PATHOLOGY via IPOLICY SOLUTIONS
2024 · second_quarter · Q2
No bill #: legislation to modernize CLIA H.R.2369 - VALID Act of 2023 FDA Final Rule: Laboratory Developed Tests S.J.Res.82 - A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests"
S.2140: Patent Eligibility Restoration Act of 2023
H.R. 9027/S. 4690 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2025
PIKE THERAPEUTICS via IPOLICY SOLUTIONS
2024 · second_quarter · RR
Treatment for Parkinson's Disease
EVERYLIFE FOUNDATION FOR RARE DISEASES via IPOLICY SOLUTIONS
2024 · second_quarter · RR
Rare Disease Center of Excellence
GUARDANT HEALTH INC. via IPOLICY SOLUTIONS
2024 · first_quarter · Q1
Contract Year 2025 Policy and Technical Changes to the Medicare Advantage Program (CMS-4205-P)
Filing targets: Centers For Medicare and Medicaid Services (CMS)
TWIST BIOSCIENCE CORPORATION via IPOLICY SOLUTIONS
2024 · first_quarter · Q1
American competitiveness in synthetic biology
S. 2333: Pandemic All Hazards Preparedness Authorization Act H.R.4702/S.2400 - Securing Gene Synthesis Act H.R. 4421: Preparing for All Hazards and Pathogens Reauthorization Act
No bill #: FY2025 Commerce, Justice, Science and Related Agencies
INVITAE INC. via IPOLICY SOLUTIONS
2024 · first_quarter · Q1
S.2140: Patent Eligibility Restoration Act
No bill #: Precision Medicine Access for Kids Today Act
H.R.2369 - VALID Act of 2023 FDA Proposed rule on LDTs
Filing targets: HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE
ASSOCIATION FOR MOLECULAR PATHOLOGY via IPOLICY SOLUTIONS
2024 · first_quarter · Q1
No bill #: legislation to modernize CLIA H.R.2369 - VALID Act of 2023 FDA Proposed Rulemaking on LDTs
S.2140: Patent Eligibility Restoration Act of 2023
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
CELLINO BIOTECH INC. via IPOLICY SOLUTIONS
2023 · fourth_quarter · Q4
Scalability of regenerative medicine technology
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GUARDANT HEALTH INC. via IPOLICY SOLUTIONS
2023 · fourth_quarter · Q4
Clinical Laboratory Fee Schedule Contract Year 2025 Policy and Technical Changes to the Medicare Advantage Program (CMS-4205-P)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
TWIST BIOSCIENCE CORPORATION via IPOLICY SOLUTIONS
2023 · fourth_quarter · Q4
FDA proposed rule on LDTs
No bill #: Labor, Health and Human Services, Education and Related Agencies Appropriations bill
S. 2333: Pandemic All Hazards Preparedness Authorization Act H.R.4702/S.2400 - Securing Gene Synthesis Act H.R. 4421: Preparing for All Hazards and Pathogens Reauthorization Act
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
INVITAE INC. via IPOLICY SOLUTIONS
2023 · fourth_quarter · Q4
No bill #: Precision Medicine Access for Kids Today Act H.R.1526: Reducing Hereditary Cancer Act
No bill #: FY2024 Labor, Health and Human Services, Education and Related Agencies Appropriations bill H.R.4366/S.2127: FY2024 Military Construction, Veterans Affairs, and Related Agencies Appropriations bill H.R.2670: National Defense Authorization Act for FY24
H.R.2369 - VALID Act of 2023 FDA Proposed rule on LDTs
ASSOCIATION FOR MOLECULAR PATHOLOGY via IPOLICY SOLUTIONS
2023 · fourth_quarter · Q4
No bill #: legislation to modernize CLIA H.R.2369 - VALID Act of 2023 FDA Proposed Rulemaking on LDTs
S.2140: Patent Eligibility Restoration Act of 2023
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELLINO BIOTECH INC. via IPOLICY SOLUTIONS
2023 · third_quarter · Q3
Regulation of Artificial Intelligence Scalability of regenerative medicine technology Health equity
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GUARDANT HEALTH INC. via IPOLICY SOLUTIONS
2023 · third_quarter · Q3
Clinical Laboratory Fee Schedule
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TWIST BIOSCIENCE CORPORATION via IPOLICY SOLUTIONS
2023 · third_quarter · Q3
No bill #: Labor, Health and Human Services, Education and Related Agencies Appropriations bill
S. 2333: Pandemic All Hazards Preparedness Authorization Act H.R.4702/S.2400 - Securing Gene Synthesis Act H.R. 4421: Preparing for All Hazards and Pathogens Reauthorization Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INVITAE INC. via IPOLICY SOLUTIONS
2023 · third_quarter · Q3
No bill #: Precision Medicine Access for Kids Today Act H.R.1526: Reducing Hereditary Cancer Act H.R. 3876/S. 2323: Access to Genetic Counseling Services Act
H.R.2369 - VALID Act of 2023 FDA RFI: Increasing Patient Access to At-Home Use Medical Technologies
S.2140: Patent Eligibility Restoration Act
ASSOCIATION FOR MOLECULAR PATHOLOGY via IPOLICY SOLUTIONS
2023 · third_quarter · Q3
S.2140: Patent Eligibility Restoration Act of 2023
No bill #: Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization Workforce shortages National Biodefense Science Board Recommendations
No bill #: Verified Innovative Testing in American Laboratories Act H.R.2369 - VALID Act of 2023 FDA Proposed Rulemaking on LDTs
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
CELLINO BIOTECH INC. via IPOLICY SOLUTIONS
2023 · third_quarter · RR
Autologous stem cell therapy
GUARDANT HEALTH INC. via IPOLICY SOLUTIONS
2023 · second_quarter · Q2
Clinical Laboratory Fee Schedule
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TWIST BIOSCIENCE CORPORATION via IPOLICY SOLUTIONS
2023 · second_quarter · Q2
No bill #: Pandemic All Hazards Preparedness Authorization Act
No bill #: Labor, Health and Human Services, Education and Related Agencies Appropriations bill
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INVITAE INC. via IPOLICY SOLUTIONS
2023 · second_quarter · Q2
No bill #: FY2024 Labor, Health and Human Services, Education and Related Agencies Appropriations bill H.R.4366/S.2127: FY2024 Military Construction, Veterans Affairs, and Related Agencies Appropriations bill H.R.2670: National Defense Authorization Act for FY24
S.2140: Patent Eligibility Restoration Act
No bill #: Right Drug Dose Now Act H.R.4189/S.2016: CONNECT for Health Act No bill #: Pharmacogenomics Education and Research Act RIN 0945-AA20, HIPAA Privacy Rule to Support Reproductive Health Care Privacy
ASSOCIATION FOR MOLECULAR PATHOLOGY via IPOLICY SOLUTIONS
2023 · second_quarter · Q2
No bill #: Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization Workforce shortages
S.2140: Patent Eligibility Restoration Act of 2023
No bill #: Verified Innovative Testing in American Laboratories Act H.R.2369 - VALID Act of 2023
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GUARDANT HEALTH INC. via IPOLICY SOLUTIONS
2023 · first_quarter · Q1
Clinical Laboratory Fee Schedule
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
TWIST BIOSCIENCE CORPORATION via IPOLICY SOLUTIONS
2023 · first_quarter · Q1
No bill #: Labor, Health and Human Services, Education and Related Agencies Appropriations bill
Request for Information; National Biotechnology and Biomanufacturing Initiative Draft NIST Internal Report (NIST IR) 8432, Cybersecurity of Genomic Data
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institute of Standards & Technology (NIST), Office of Science & Technology Policy (OSTP), SENATE
INVITAE INC. via IPOLICY SOLUTIONS
2023 · first_quarter · Q1
No bill #: Right Drug Dose Now Act No bill#: CONNECT for Health Act
No bill #: Patent Eligibility Restoration Act
H.R.2369 - VALID Act of 2023
ASSOCIATION FOR MOLECULAR PATHOLOGY via IPOLICY SOLUTIONS
2023 · first_quarter · Q1
No bill #: Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization Workforce shortages
No bill #: Verified Innovative Testing in American Laboratories Act H.R.2369 - VALID Act of 2023
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
GUARDANT HEALTH INC. via IPOLICY SOLUTIONS
2023 · first_quarter · RR
Clinical laboratory fee schedule pricing policy
GENEDX, INC. via IPOLICY SOLUTIONS
2022 · second_quarter · 2A
HR 4128/S 2209 Verifying Accurate Leading-Edge IVCT Development (VALID) Act Coverage S.4348 - FDASLA Act of 2022
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EVERLY HEALTH (FORMERLY KNOWN AS EVERLYWELL) via IPOLICY SOLUTIONS
2022 · second_quarter · 2A
S.4348 - FDASLA Act of 2022
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TWIST BIOSCIENCE CORPORATION via IPOLICY SOLUTIONS
2022 · second_quarter · 2A
Biosecurity standards American competitiveness H.R.4521/S.1418 Bioeconomy Research and Development Act of 2021 H.R.4521 - America COMPETES Act S.1260 - United States Innovation and Competition Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SEMA4 (FORMERLY KNOWN AS MOUNT SINAI GENOMICS, INC. (D/B/A SEMA4)) via IPOLICY SOLUTIONS
2022 · second_quarter · 2A
S.4348 - FDASLA Act of 2022
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INVITAE INC. via IPOLICY SOLUTIONS
2022 · second_quarter · 2A
HR 4128/S 2209 Verifying Accurate Leading-Edge IVCT Development (VALID) Act Coverage S.4348 - FDASLA Act of 2022 FDA Draft Guidance on ctDNA
H.R.8152 American Data Privacy and Protection Act
H.R. 6000 Cures 2.0 Act H.R.6875 - Right Drug Dose Now Act S.3799 - PREVENT Pandemics Act Cancer Moonshot
ASSOCIATION FOR MOLECULAR PATHOLOGY via IPOLICY SOLUTIONS
2022 · second_quarter · 2A
S.3799, PREVENT Pandemics Act Pandemic response and supply chain issues
U.S. Patent Act Sec. 101 Reforms
HR 4128/S 2209 Verifying Accurate Leading-Edge IVCT Development (VALID) Act Coverage S 1666, Verified Innovative Testing in American Laboratories (VITAL) Act S.4348 - FDASLA Act of 2022
Filing targets: HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE
TWIST BIOSCIENCE CORPORATION via IPOLICY SOLUTIONS
2022 · fourth_quarter · Q4
Biosecurity standards American competitiveness Pub.L. 117-167 - CHIPS and Science Act Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Science & Technology Policy (OSTP), SENATE
INVITAE INC. via IPOLICY SOLUTIONS
2022 · fourth_quarter · Q4
H.R. 6000 Cures 2.0 Act H.R.6875 - Right Drug Dose Now Act Diversity in clinical trials Health equity
S.4734 Patent Eligibility Restoration Act
H.R.2617 - Consolidated Appropriations Act, 2023
ASSOCIATION FOR MOLECULAR PATHOLOGY via IPOLICY SOLUTIONS
2022 · fourth_quarter · Q4
Health data privacy
S.4734 Patent Eligibility Restoration Act
HR 4128/S 2209 Verifying Accurate Leading-Edge IVCT Development (VALID) Act Coverage S 1666, Verified Innovative Testing in American Laboratories (VITAL) Act Laboratory testing for Mpox
23ANDME, INC. via IPOLICY SOLUTIONS
2022 · fourth_quarter · Q4
Direct to consumer genetic testing No bill number, Consumer Genetic Data Privacy Act of 2022 H.R. 8152, the American Data Privacy and Protection Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CLEAR LABS via IPOLICY SOLUTIONS
2022 · third_quarter · 3T
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023
Filing targets: SENATE
GENEDX, INC. via IPOLICY SOLUTIONS
2022 · second_quarter · 2T
HR 4128/S 2209 Verifying Accurate Leading-Edge IVCT Development (VALID) Act Coverage S.4348 - FDASLA Act of 2022
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EVERLY HEALTH (FORMERLY KNOWN AS EVERLYWELL) via IPOLICY SOLUTIONS
2022 · third_quarter · Q3
S.4348 - FDASLA Act of 2022
Insurance coverage at-home specimen collection
H.R.4040 Advancing Telehealth Beyond COVID-19 Act of 2021
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TWIST BIOSCIENCE CORPORATION via IPOLICY SOLUTIONS
2022 · third_quarter · Q3
Biosecurity standards American competitiveness H.R.4521/S.1418 Bioeconomy Research and Development Act of 2021 H.R.4521 - America COMPETES Act S.1260 - United States Innovation and Competition Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Science & Technology Policy (OSTP), SENATE
INVITAE INC. via IPOLICY SOLUTIONS
2022 · third_quarter · Q3
H.R.5989 - Precision Medicine Answers for Kids Today Act Enhancing Oncology Model Information blocking
H.R. 6000 Cures 2.0 Act H.R.6875 - Right Drug Dose Now Act Cancer Moonshot
S.4734 Patent Eligibility Restoration Act
ASSOCIATION FOR MOLECULAR PATHOLOGY via IPOLICY SOLUTIONS
2022 · third_quarter · Q3
HR 4128/S 2209 Verifying Accurate Leading-Edge IVCT Development (VALID) Act Coverage S 1666, Verified Innovative Testing in American Laboratories (VITAL) Act S.4348 - FDASLA Act of 2022
S.3799, PREVENT Pandemics Act Pandemic response and supply chain issues Laboratory workforce
S.4734 Patent Eligibility Restoration Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE
23ANDME, INC. via IPOLICY SOLUTIONS
2022 · third_quarter · Q3
Direct to consumer genetic testing No bill number, Consumer Genetic Data Privacy Act of 2022 H.R. 8152, the American Data Privacy and Protection Act
Filing targets: HOUSE OF REPRESENTATIVES
GENEDX, INC. via IPOLICY SOLUTIONS
2022 · second_quarter · Q2
HR 4128/S 2209 Verifying Accurate Leading-Edge IVCT Development (VALID) Act Coverage S.4348 - FDASLA Act of 2022
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CLEAR LABS via IPOLICY SOLUTIONS
2022 · second_quarter · Q2
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023
Filing targets: SENATE
EVERLY HEALTH (FORMERLY KNOWN AS EVERLYWELL) via IPOLICY SOLUTIONS
2022 · second_quarter · Q2
S.4348 - FDASLA Act of 2022
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TWIST BIOSCIENCE CORPORATION via IPOLICY SOLUTIONS
2022 · second_quarter · Q2
Biosecurity standards American competitiveness H.R.4521/S.1418 Bioeconomy Research and Development Act of 2021 H.R.4521 - America COMPETES Act S.1260 - United States Innovation and Competition Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SEMA4 (FORMERLY KNOWN AS MOUNT SINAI GENOMICS, INC. (D/B/A SEMA4)) via IPOLICY SOLUTIONS
2022 · second_quarter · Q2
S.4348 - FDASLA Act of 2022
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INVITAE INC. via IPOLICY SOLUTIONS
2022 · second_quarter · 2A
H.R.8152 American Data Privacy and Protection Act
U.S. Patent Act Sec. 101 reform
H.R.5989 - Precision Medicine Answers for Kids Today Act Molecular Pathology Coding and Reimbursement Oncology Care Model Medicare Promoting Interoperability Program Information blocking
INVITAE INC. via IPOLICY SOLUTIONS
2022 · second_quarter · Q2
HR 4128/S 2209 Verifying Accurate Leading-Edge IVCT Development (VALID) Act Coverage S.4348 - FDASLA Act of 2022 FDA Draft Guidance on ctDNA
H.R.8152 American Data Privacy and Protection Act
U.S. Patent Act Sec. 101 reform
ASSOCIATION FOR MOLECULAR PATHOLOGY via IPOLICY SOLUTIONS
2022 · second_quarter · Q2
HR 4128/S 2209 Verifying Accurate Leading-Edge IVCT Development (VALID) Act Coverage S 1666, Verified Innovative Testing in American Laboratories (VITAL) Act S.4348 - FDASLA Act of 2022
U.S. Patent Act Sec. 101 Reforms
S.3799, PREVENT Pandemics Act Pandemic response and supply chain issues
Filing targets: HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE
H.R.9260: Labor, Health and Human Services, Education, and Related Agencies FY 2027 No bill number, Senate: Defense FY 2027
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
H.R. 2036/ S.925: Credit for Caring Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
No bill #: Securing Gene Synthesis Act No bill #: Gene Synthesis Safety and Security Act H.R. 3029: Nucleic Acid Standards for Biosecurity Act
No bill #: Commerce, Justice, Science, and Related Agencies Appropriations Act
Filing targets: Bureau of Industry and Security (BIS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Natl Security Council (NSC), SENATE, U.S. Trade Representative (USTR)
H.R. 2036/ S.925: Credit for Caring Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CMS Deregulation RFI: prior authorization, NCCI manual inconsistencies, CLFS payment reform
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
HR 694/S 206 Restoring Trade Fairness Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Medicaid and the Supplemental Nutrition Assistance Program
Credit for Caring Act
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
HR 2471: Right Drug Dose Now Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
H.R. 9027/S. 4690 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2025
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Intellectual property theft
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S.2140: Patent Eligibility Restoration Act of 2023
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Intellectual property theft
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S2140 Patent Eligibility Restoration Act Intellectual property theft
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S.2140: Patent Eligibility Restoration Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
No bill #: Right Drug Dose Now Act No bill #: Pharmacogenomics Education and Research Act FTC-2023-0037 Health Breach Notification Rule, Project No. P205405
No bill #: FY2024 Labor, Health and Human Services, Education and Related Agencies Appropriations bill H.R.4366/S.2127: FY2024 Military Construction, Veterans Affairs, and Related Agencies Appropriations bill H.R.2670: National Defense Authorization Act for FY24
Filing targets: Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
No bill #: Precision Medicine Access for Kids Today Act
H.R.2369 - VALID Act of 2023 FDA Guidance, Docket No. FDA-2022-D-2983 for Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products FDA public meeting, FDA-2018-N-4002 Electronic Submission of Adverse Event Reports to FAERS Using ICH E2B(R3) Standards FDA guidance, Docket No. FDA-2023-D-0110: Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
No bill #: Precision Medicine Access for Kids Today Act H.R.1789/S.642 Finn Sawyer Access to Cancer Testing Act H.R.1526/S.765 Reducing Hereditary Cancer Act CMS-9898-NC, Request for Information; Essential Health Benefits. 87FR76044; Healthcare System Level Strategies to Address Racial/Ethnic and Related Disparities in Health and Healthcare Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; Advancing Interoperability and Improving Prior Authorization Processes for Medicare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Childrens Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-Facilitated Exchanges, Merit-Based Incentive Payment System (MIPS) Eligible Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program (CMS-0057-P)
No bill #: FY2024 Labor, Health and Human Services, Education and Related Agencies Appropriations bill No bill number: FY2024 Military Construction, Veterans Affairs, and Related Agencies Appropriations bill No bill #: Military Construction, Veterans Affairs, and Related Agencies Appropriations bill
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
H.R.5989 - Precision Medicine Answers for Kids Today Act Molecular Pathology Coding and Reimbursement Oncology Care Model Medicare Promoting Interoperability Program Information blocking
U.S. Patent Act Sec. 101 reform
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Science & Technology Policy (OSTP), SENATE
HR 4128/S 2209 Verifying Accurate Leading-Edge IVCT Development (VALID) Act Coverage
H.R.5989 - Precision Medicine Answers for Kids Today Act Enhancing Oncology Model Section 112 of title I of Division BB of the Consolidated Appropriations Act 2021
H.R.8152 American Data Privacy and Protection Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Science & Technology Policy (OSTP), SENATE
S.3799, PREVENT Pandemics Act
Filing targets: Centers For Disease Control & Prevention (CDC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE
HR 4128/S 2209 Verifying Accurate Leading-Edge IVCT Development (VALID) Act Coverage S.4348 - FDASLA Act of 2022
H.R.8152 American Data Privacy and Protection Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
H.R. 6000 Cures 2.0 Act H.R.6875 - Right Drug Dose Now Act S.3799 - PREVENT Pandemics Act Cancer Moonshot
HR 4128/S 2209 Verifying Accurate Leading-Edge IVCT Development (VALID) Act Coverage S.4348 - FDASLA Act of 2022 FDA Draft Guidance on ctDNA
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Science & Technology Policy (OSTP), SENATE
H.R.5989 - Precision Medicine Answers for Kids Today Act Molecular Pathology Coding and Reimbursement Oncology Care Model
H.R. 6000 Cures 2.0 Act H.R.6875 - Right Drug Dose Now Act S.3799 - PREVENT Pandemics Act Cancer Moonshot
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Science & Technology Policy (OSTP), SENATE